Lower Lenvatinib Starting Doses Show No Clear Advantage in Advanced Endometrial Cancer
A new systematic review and meta-analysis finds that starting lenvatinib below 20 mg with pembrolizumab neither clearly preserves tumor response ...
Tag: observational evidence
POPULAR NEWS
-
Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone
-
Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes
-
Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells
-
New Scale Measures How Ready Nurse Educators Really Are for the AI Era